Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Krisztina Zsebo
|
| gptkbp:focus |
gptkb:cardiovascular_disease
gene therapy |
| gptkbp:foundedYear |
2000
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celladon Corporation
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mergedInto |
gptkb:Eiger_BioPharmaceuticals
2016 |
| gptkbp:notableEvent |
failed Phase 2b CUPID2 trial in 2015
|
| gptkbp:notableProduct |
Mydicar
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CLDN
|
| gptkbp:bfsParent |
gptkb:Patrick_Y._Yang
|
| gptkbp:bfsLayer |
8
|